Amgen (AMGN) T-Vec Expectations Low; RBC Comments Following FDA Briefing Docs
Tweet Send to a Friend
RBC Capital maintained an Outperform rating on Amgen (NASDAQ: AMGN) with a price target of $185. Shares declined after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE